United States Patent 8,901,123: Scope, Claims, and US Landscape for a c-Met Inhibitor
US patent 8,901,123 claims methods of inhibiting c-Met (a receptor tyrosine kinase) and related HGF/c-Met signaling using a single small-molecule active agent: 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide dihydrochloric acid (plus hydrates/solvates). The independent scope is concentrated on method-of-use rather than broad composition-of-matter claims in the excerpts provided.
What do the claims cover, in plain scope terms?
All three independent claim statements (they appear as claim set 1 to 3 in the provided text) are anchored to the same compound and the same target axis:
-
Active agent (fixed in each claim):
2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide dihydrochloric acid, including hydrates and solvates.
-
Target (fixed in claim 1, functional in claims 2-3):
“a receptor or non-receptor tyrosine kinase” with the kinase specified as c-Met in claim 1.
-
Biological outcomes (the claimed “method” steps):
1) Inhibiting activity of c-Met kinase by contacting with the compound
2) Inhibiting the HGF/c-Met signaling pathway in a cell
3) Inhibiting proliferative activity of a cell
Claim-by-claim breakdown
| Claim |
Type |
Core method step |
Biological/clinical linkage in claim text |
Key limiting elements |
| 1 |
Method |
Contact kinase with the specified compound |
“Inhibiting activity of a receptor or non-receptor tyrosine kinase” and kinase is c-Met |
Fixed compound identity; fixed target c-Met |
| 2 |
Method (cell-based) |
Contact a cell with the compound |
Inhibiting HGF/c-Met kinase signaling pathway |
Fixed compound identity; cell-based; pathway described as HGF/c-Met |
| 3 |
Method (cell-based) |
Contact a cell with the compound |
Inhibiting proliferative activity of a cell |
Fixed compound identity; proliferation as functional endpoint |
Scope consequence: with the compound fixed and the c-Met/HGF axis specified, the patent’s enforceable footprint (on methods) is strongest where an accused product is used to modulate c-Met signaling and downstream proliferation in cell contexts aligned with those pathways.
How broad is the scope across product and use?
1) Fixed chemical identity narrows the “who”
The method claims require contacting with a specific chemical salt form and also cover hydrates/solvates. That is a hard tie to the claimed compound’s chemical identity.
- Claim language expressly includes “dihydrochloric acid salt”.
- It also includes “a hydrate or solvate thereof.”
Practical implication: a materially different salt form, free base, or different stereochemical variant (if any exist) would not fall within the literal claim language unless it still meets the “dihydrochloric acid salt” and hydrate/solvate definitions.
2) Target specificity narrows the “what pathway”
Claim 1 explicitly locks the kinase to c-Met. Claims 2 and 3 use pathway and phenotypic endpoints that are commonly downstream of c-Met activation by HGF.
Practical implication: the claims are best positioned against uses where c-Met/HGF signaling is the operative mechanism. They are not written broadly as “tyrosine kinase signaling” without the c-Met/HGF frame.
3) “Contacting” is operationally broad on administration formats
“Contacting” a kinase or cell is a functional step that can be satisfied by ex vivo assays, in vitro treatments, or in vivo dosing where the biological system is exposed to the compound.
Practical implication: the claims can cover a wide range of experimental and potentially clinical dosing paradigms, as long as the asserted biological endpoints are met and the compound is the claimed one.
What limitations are baked into the claim language?
Hard limitations
- Compound identity: must be the listed dihydrochloric acid salt or hydrate/solvate.
- Target and pathway:
- Claim 1 requires c-Met as the kinase.
- Claim 2 requires the HGF/c-Met signaling pathway in a cell.
- Functional endpoints:
- Claim 3 requires inhibition of proliferative activity of a cell.
Soft limitations (still constraining, but phrased broadly)
- Claim 1 starts with “a receptor or non-receptor tyrosine kinase,” but then specifies c-Met; this is not truly open-ended once c-Met is imposed.
- Claims 2-3 describe “in a cell” without restricting cell type. That widens coverage across cell lines, but still requires that the pathway inhibition and/or proliferation inhibition occur under the defined treatment.
How does this claim set map to infringement theories?
Given the claims are method-of-use and tied to a single compound, typical enforcement focuses on proving:
1) Exposure: accused dosing or assay conditions involve the claimed compound (or covered hydrate/solvate).
2) Mechanistic relevance: the treatment inhibits c-Met activity or HGF/c-Met signaling in cells.
3) Phenotypic effect: treatment inhibits cell proliferation.
In practice, proving mechanistic inhibition often relies on:
- p-Met (phospho-Met) readouts,
- downstream signaling markers (commonly downstream of c-Met/HGF, though not enumerated in the claim text),
- or functional proliferation assays.
What is the likely patent landscape around US 8,901,123 (scope adjacent space)?
A strong landscape view requires complete bibliographic context (assignee, priority, and family members) and a full claim set. Those elements are not provided in the prompt beyond the claim text for claims 1-3. With only these claims, the landscape can still be characterized by what neighboring US filings and enforcement targets typically exist for c-Met inhibitors, and how this patent sits relative to likely competitors on claim strategy.
1) Landscape sector: c-Met/HGF pathway inhibitors
The patent sits in the “c-Met/HGF inhibition” lane. Other patents commonly compete in one of two ways:
- Compound patents (composition of matter): broad structural coverage for small molecules targeting c-Met.
- Use patents (method-of-use): specific biological pathways and outcomes like HGF/c-Met inhibition and anti-proliferative effects.
Where this patent fits: these claims look like use claims that can be asserted even if another party has composition-of-matter freedom, provided they use the claimed chemical or covered hydrate/solvate.
2) Landscape pressure point: fixed salt and hydrate/solvate coverage
Many c-Met inhibitor programs generate multiple salts and solvates. This patent’s explicit inclusion of “dihydrochloric acid salt” and “a hydrate or solvate thereof” reduces easy design-around options but still leaves room for:
- salts not captured by “dihydrochloric acid,”
- free base forms, if not claimed by equivalents and if claim construction stays literal.
Without the full specifications and claim set, it is not possible to determine how aggressively the patent uses generic language or whether fallback embodiments exist to capture alternate salt forms.
3) Landscape pressure point: method endpoints are generic but target-locked
“Proliferative activity” is a broad functional endpoint. Many competitors seek to avoid direct overlap by:
- targeting c-Met but not claiming/pursuing proliferation-specific use in cell contexts, or
- framing uses around other endpoints not tied to proliferation, or
- pursuing different targets (other kinases) as primary.
This patent’s claim 2 explicitly calls out HGF/c-Met signaling pathway, which is a more mechanistic tie than proliferation alone. That makes it harder to argue that c-Met inhibition is not implicated if the accused product is a true c-Met/HGF inhibitor in cell systems.
What does the claim language imply about priority and enforceability windows?
The enforceability window depends on priority date, filing date, examination history, and any terminal disclaimers. Those are not provided. So only claim-logic can be stated:
- The patent offers method-of-use coverage that generally can be asserted through induced infringement if product use conditions meet “contacting” and the mechanistic/proliferation endpoints.
Practical implication: even if composition-of-matter is contested or expires earlier, method claims tied to the same compound may remain a separate barrier until expiration or invalidation.
Is there meaningful claim redundancy or dependency across claims 1-3?
Yes, the claims are layered:
- Claim 1: kinase activity inhibition with c-Met specified.
- Claim 2: cell-based inhibition of HGF/c-Met signaling pathway.
- Claim 3: cell-based inhibition of proliferative activity.
This layering increases enforceability because the patentee can select the easiest endpoint to prove:
- If mechanistic assays are strongest, assert claim 1 or claim 2.
- If proliferation assays are easiest, assert claim 3.
How could a competitor design around based on these claim limitations?
Based strictly on what is present in claims 1-3:
Design-around routes (literal)
- Use a different salt form or chemical form that is not “dihydrochloric acid salt” and not a covered hydrate/solvate under claim construction.
- Avoid use where c-Met/HGF inhibition or cell proliferation inhibition is the asserted and provable result.
Design-around routes (strategy)
- If developing a c-Met inhibitor, compete on other compounds and avoid the exact chemical identity.
- If using the same compound, develop regulatory or commercial positioning that disputes whether the administered agent truly meets the mechanistic endpoints in the claimed “cell” contexts.
What business conclusions follow from the scope?
1) The patent’s enforceable value is concentrated on the specific compound identity. If an accused product uses the same dihydrochloride form (or a covered hydrate/solvate), the method claims map cleanly to common c-Met functional testing and likely common therapeutic rationales.
2) The main scientific hook is the HGF/c-Met axis. Claim 2 creates a mechanistic claim path that is often directly testable with cell-based pathway assays.
3) There is meaningful evidentiary flexibility across claims 1-3 because each claim uses a different but related endpoint (kinase activity, pathway signaling, proliferation).
4) Design-around is more difficult when challengers use the same salt/hydrate/solvate family. The inclusion language blocks some straightforward reformulation tactics.
Key Takeaways
- US 8,901,123 claims methods where the fixed active is 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide dihydrochloric acid, including hydrates/solvates.
- Target lock: c-Met is explicitly specified in claim 1 and appears as HGF/c-Met signaling in claim 2.
- Phenotype lock: claim 3 requires inhibition of proliferative activity in cells.
- Enforcement leverage: claim set supports multiple evidentiary paths (mechanistic or phenotypic) while tying the accused use to the same compound identity.
- Landscape position: this patent sits in the c-Met/HGF inhibition method-of-use space and is most relevant where competitors use the claimed compound (or covered forms) for c-Met-driven signaling and proliferation inhibition.
FAQs
1) Does US 8,901,123 claim the compound itself?
The excerpted claims 1-3 are framed as methods of inhibiting using the specified compound. They are not composition-of-matter claims in the text provided.
2) Is c-Met explicitly required?
Yes. Claim 1 specifies the kinase is c-Met, and claim 2 specifies inhibition of HGF/c-Met signaling.
3) What forms of the drug are included?
The claims cover the dihydrochloric acid salt and also hydrates or solvates thereof.
4) Are the method claims limited to specific cell types?
No cell type is specified in claims 2-3; they are written as “a cell,” with the functional endpoints tied to HGF/c-Met signaling and proliferation.
5) What is the cleanest claim to prove in litigation?
From the claim text alone, evidentiary options exist across claims 1-3. If mechanistic assays are available, claim 2 (HGF/c-Met pathway) or claim 1 (c-Met activity) tends to be direct; if only growth endpoints are strong, claim 3 is a direct route.
References
[1] US Patent 8,901,123 (claims 1-3 as provided in the prompt).
